-
Je něco špatně v tomto záznamu ?
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
NW. Clarke, AJ. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, J. de Menezes, G. Girotto, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, JY. Joung, M. Sugimoto, JA. Virizuela, U. Emmenegger, J. Navratil, GL....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed
38319800
DOI
10.1056/evidoa2200043
Knihovny.cz E-zdroje
- MeSH
- androsteny MeSH
- ftalaziny * MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci * farmakoterapie MeSH
- piperaziny * MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo in the first-line setting. Imaging-based progression-free survival was 24.8 months for patients treated with abiraterone and olaparib versus 16.6 months for those receiving abiraterone alone.
Ashford Cancer Centre Research Adelaide South Australia
Carolina Urologic Research Center Myrtle Beach SC
Centre Hospitalier de l'Universite de Montreal Montreal
Centre Hospitalier Intercommunal de Cornouaille Quimper France
Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz Besançon France
Centro de Investigaciones Clinicas Viña del Mar Valparaíso Chile
Duke Cancer Institute Center for Prostate and Urologic Cancer Duke University Durham NC
Fondazione Istituto Nazionale Tumori Milano Milan
Global Medicines Development Oncology R and D AstraZeneca Cambridge United Kingdom
Global Medicines Development Oncology R and D AstraZeneca Gaithersburg MD
Hospital de Base São José do Rio Preto São José do Rio Preto Brazil
Hospital Nossa Senhora da Conceição Porte Alegre Brazil
Hospital Universitario Virgen Macarena Seville Spain
Izmir Economy University Medical Park Hospital Karsiyaka Turkey
Kagawa University Hospital Kagawa Japan
Kaiser Permanente Southern California Los Angeles
Keio University School of Medicine Tokyo
Masaryk Memorial Cancer Institute Brno Czech Republic
National Cancer Center Goyang South Korea
Radboud Universitair Medisch Centrum Nijmegen Netherlands
Sunnybrook Research Institute and Odette Cancer Centre Toronto
Translational Medicine Oncology R and D AstraZeneca Cambridge United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007930
- 003
- CZ-PrNML
- 005
- 20240903092645.0
- 007
- ta
- 008
- 240412s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1056/EVIDoa2200043 $2 doi
- 035 __
- $a (PubMed)38319800
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Clarke, Noel W $u The Christie and Salford Royal Hospital NHS Foundation Trusts, University of Manchester, Manchester, United Kingdom
- 245 10
- $a Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer / $c NW. Clarke, AJ. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, J. de Menezes, G. Girotto, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, JY. Joung, M. Sugimoto, JA. Virizuela, U. Emmenegger, J. Navratil, GL. Buchschacher, C. Poehlein, EA. Harrington, C. Desai, J. Kang, F. Saad
- 520 9_
- $a Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo in the first-line setting. Imaging-based progression-free survival was 24.8 months for patients treated with abiraterone and olaparib versus 16.6 months for those receiving abiraterone alone.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory prostaty rezistentní na kastraci $x farmakoterapie $7 D064129
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a androsteny $7 D000736
- 650 12
- $a ftalaziny $7 D010793
- 650 12
- $a piperaziny $7 D010879
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Armstrong, Andrew J $u Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC
- 700 1_
- $a Thiery-Vuillemin, Antoine $u Centre Hospitalier Régional Universitaire Hôpital Jean-Minjoz, Besançon, France
- 700 1_
- $a Oya, Mototsugu $u Keio University School of Medicine, Tokyo
- 700 1_
- $a Shore, Neal $u Carolina Urologic Research Center, Myrtle Beach, SC
- 700 1_
- $a Loredo, Eugenia $u Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
- 700 1_
- $a Procopio, Giuseppe $u Fondazione Istituto Nazionale Tumori Milano, Milan
- 700 1_
- $a de Menezes, Juliana $u Hospital Nossa Senhora da Conceição, Porte Alegre, Brazil
- 700 1_
- $a Girotto, Gustavo $u Hospital de Base São José do Rio Preto, São José do Rio Preto, Brazil
- 700 1_
- $a Arslan, Cagatay $u Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
- 700 1_
- $a Mehra, Niven $u Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
- 700 1_
- $a Parnis, Francis $u Ashford Cancer Centre Research, Adelaide, South Australia
- 700 1_
- $a Brown, Emma $u University Hospital Southampton, Southampton, United Kingdom
- 700 1_
- $a Schlürmann, Friederike $u Centre Hospitalier Intercommunal de Cornouaille, Quimper, France
- 700 1_
- $a Joung, Jae Y $u National Cancer Center, Goyang, South Korea
- 700 1_
- $a Sugimoto, Mikio $u Kagawa University Hospital, Kagawa, Japan
- 700 1_
- $a Virizuela, Juan A $u Hospital Universitario Virgen Macarena, Seville, Spain
- 700 1_
- $a Emmenegger, Urban $u Sunnybrook Research Institute and Odette Cancer Centre, Toronto
- 700 1_
- $a Navrátil, Jiří $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $7 xx0164164
- 700 1_
- $a Buchschacher, Gary L $u Kaiser Permanente Southern California, Los Angeles
- 700 1_
- $a Poehlein, Christian $u Merck & Co., Inc., Rahway, NJ
- 700 1_
- $a Harrington, Elizabeth A $u Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- 700 1_
- $a Desai, Chintu $u Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
- 700 1_
- $a Kang, Jinyu $u Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD
- 700 1_
- $a Saad, Fred $u Centre Hospitalier de l'Universite de Montreal, Montreal
- 773 0_
- $w MED00214736 $t NEJM evidence $x 2766-5526 $g Roč. 1, č. 9 (2022), s. EVIDoa2200043
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38319800 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240903092642 $b ABA008
- 999 __
- $a ok $b bmc $g 2081743 $s 1217697
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 1 $c 9 $d EVIDoa2200043 $e 20220603 $i 2766-5526 $m NEJM evidence $n NEJM Evid $x MED00214736
- LZP __
- $a Pubmed-20240412
